3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
21
Lung Neoplasms
10
Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
6
Skin Neoplasms
6
Prostatic Neoplasms
5
Neoplasm Metastasis
5
Melanoma
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Merkel Cell
4
Breast Neoplasms
4
Pancreatic Neoplasms
3
Mycosis Fungoides
3
Carcinoma, Squamous Cell
3
Carcinoma, Hepatocellular
3
Carcinoma, Basal Cell
3
Adenocarcinoma
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Sarcoma
2
Rectal Neoplasms
2
Oropharyngeal Neoplasms
2
Mouth Neoplasms
2
Mesothelioma, Malignant
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Interventions
pembrolizumab
4
Trastuzumab
4
Oxaliplatin
4
Fluorouracil
4
Cyclophosphamide
4
Carboplatin
4
Radiotherapy
3
Paclitaxel
3
Endoscopy
3
Docetaxel
3
Cytarabine
3
Chemoradiotherapy
3
Capecitabine
3
toripalimab
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Observation
2
Neoadjuvant Therapy
2
Metformin
2
Magnetic Resonance Imaging
2
Leucovorin
2
Irinotecan
2
Immunotherapy
2
Immune Checkpoint Inhibitors
2
Epirubicin
2
Drug Therapy
2
Doxorubicin
2
Cisplatin
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pathologic Complete Response
×
cemiplimab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled